Small molecule · Inhibitor of Thymidylate synthase (TYMS)
Fosifloxuridine nafalbenamide is a phosphoramidate prodrug of the monophosphate form of 5-fluoro-2'-deoxyuridine, which is taken up by tumor cells and converted to FUDR-MP. FUDR-MP inhibits thymidylate synthase, depleting thymidine triphosphate and DNA synthesis. It is studied in colorectal cancer and other solid tumors and melanoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05714553 | Phase 1/2 | Advanced Cancer | Terminated | NCNA |
| NCT03428958 | Phase 1/2 | Colorectal Cancer | Completed | NCNA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced CancerAdvanced Solid TumorClassical Hodgkin LymphomaColorectal CancerColorectal CarcinomaColorectal NeoplasmsColorectal TumorsHead and Neck Squamous Cell CarcinomaMelanomaMetastatic CancerNeoplasm MalignantNeoplasms, ColorectalNon Small Cell Lung CancerRenal Cell Carcinoma
Updated Oct 25, 2026.